Survival after resistance to amivantamab

Regarding the survival period after resistance to Amivantamab (Amivantamab), it needs to be clear that the long-term data on the clinical application of this new drug is still relatively limited because Amivantamab is a newer drug. Survival after resistance is often affected by multiple factors, including resistance mechanisms, individual differences, the patient's overall health, and the availability of other treatment options. However, there are insufficient research data to accurately describe the median or specific values u200bu200bof survival after evantumumab resistance.

Typically, for cancer treatments, survival is often shorter after drug resistance, because drug resistance indicates that previously used treatments are no longer effective. In this case, doctors often consider switching to other treatment options, such as chemotherapy, immunotherapy, or other targeted therapies. Decisions about treatment selection are often made based on the patient's condition, molecular characteristics, and treatment history.

Research and clinical trials of evantumumab are ongoing, and over time we will have more information about its long-term effects and management of resistance. The specific situation of survival after drug resistance will become clearer as more research and clinical experience accumulate.

Patients and doctors need to actively cooperate when dealing with post-drug resistance situations and seek the best treatment options, including clinical trials, individualization of treatment plans and comprehensive supportive care, to improve patients' quality of life. Post-resistance treatment often requires multifaceted considerations, so close collaboration between patient and physician is crucial.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.